⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21805122 | 0.78 | HSD11B1 (0.36) | — | |
| SCHEMBL21805081 | 0.77 | TUBB1 (0.32) | — | |
| SCHEMBL21805983 | 0.77 | CCR2 (0.31) | — | |
| SCHEMBL20500560 | 0.74 | PDE4A (0.36) | — | |
| SCHEMBL29404742 | 0.71 | TUBB1 (0.31) | — | |
| SCHEMBL21806070 | 0.70 | LMNA (0.34) | — | |
| SCHEMBL2484983 | 0.69 | MTOR (0.39) | — | |
| SCHEMBL22083808 | 0.67 | ALDH1A1 (0.42) | — | |
| SCHEMBL22347234 | 0.67 | UHRF1 (0.37) | — | |
| SCHEMBL29405386 | 0.67 | TUBB1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289821-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | ELI LILLY AND COMPANY | 2025-09-18 | — | — | US | disclosed |
| EP-3852748-B1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | LILLY CO ELI (US) | 2025-09-03 | — | — | EP | disclosed |
| EP-4596543-A2 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | Organovo, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20230382913-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | ORGANOVO, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230382913-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | ORGANOVO, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230382913-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | ORGANOVO, INC. | 2023-11-30 | — | — | US | disclosed |
| US-11773094-B2 | Farnesoid X receptor agonists and uses thereof | ORGANOVO, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773094-B2 | Farnesoid X receptor agonists and uses thereof | ORGANOVO, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773094-B2 | Farnesoid X receptor agonists and uses thereof | ORGANOVO, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20220054469-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | METACRINE, INC. | 2022-02-24 | — | — | US | disclosed |
| US-11084817-B2 | Farnesoid X receptor agonists and uses thereof | METACRINE, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| EP-3852737-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | Metacrine, Inc. (US) | 2021-07-28 | — | — | EP | disclosed |
| EP-3852736-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | Metacrine, Inc. (US) | 2021-07-28 | — | — | EP | disclosed |
| US-20200102308-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | ELI LILLY AND COMPANY | 2020-04-02 | — | — | US | disclosed |
| US-20200102308-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | ELI LILLY AND COMPANY | 2020-04-02 | — | — | US | disclosed |
| WO-2020061112-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | METACRINE, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
| WO-2020061118-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | METACRINE, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
| WO-2020061112-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | METACRINE, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
| WO-2020061117-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | METACRINE, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
| WO-2020061116-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | METACRINE, INC. (US) | 2020-03-26 | — | — | WO | disclosed |